Press Releases

PPTA Comments to FDA

Dear Sir or Madam:

The Plasma Protein Therapeutics Association ("PPTA" or "Association") commends the Food and Drug Administration ("FDA" or "Agency") for addressing the critical issue of drug shortages through its February 2012 draft Guidance to industry, "Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage" ("Draft Guidance").

Continue reading

  • Created on .

PPTA Recognizes International Rare Disease Day 2012

ANNAPOLIS, MD – Plasma Protein Therapeutics Association (PPTA) joins over 300 organizations in 56 countries in recognizing International Rare Disease Day. This event, now in its fifth year, seeks to raise awareness among the general public and decision makers about rare diseases, impacting lives all over the globe.

Continue reading

  • Created on .

PPTA Attends FDA Public Workshop on Drug Shortages

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) attended a U.S. Food and Drug Administration (FDA)–sponsored workshop to address growing concerns regarding drug shortages in certain sectors of the pharmaceutical industry September 26.

Continue reading

  • Created on .

IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) believes the Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual pharmaceutical fee undermines patients with rare diseases and fails to take into account concerns expressed by leading consumer organizations and Congress.

Continue reading

  • Created on .
Copyright © 2020 PPTA. All rights reserved. (202) 789-3100